Litigation

Array BioPharma, Inc. v. Teva Pharmaceuticals, Inc.

settled

1:23-cv-00625-GBW

Auto-generating section 1 of 4: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Filed
2023-06-08
Terminated
2025-08-01

Patents at issue (4)

9314464
9562016
9598376
9980944

Summary

Hatch-Waxman ANDA litigation brought by Array BioPharma against Teva over Teva's generic binimetinib 15 mg tablets (ANDA No. 217509). The case ended in a stipulated dismissal/settlement after briefing on Teva's stay motion pending appeal of the crystallized binimetinib claim construction from the Alembic/Sandoz litigation. Although U.S. 9,314,464 appeared on the case's USPTO report, the narrative states Array asserted only the three Crystallized Binimetinib Patents (U.S. 9,562,016; 9,598,376; 9,980,944) against Teva, and Teva's Paragraph IV notice did not address the '464 patent.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).